Keyphrases
Non-Hodgkin Lymphoma
63%
Diffuse Large B-cell Lymphoma (DLBCL)
46%
Chronic Myeloid Leukemia
44%
Serum Ferritin
42%
Surabaya
42%
Chemotherapy
37%
Iron Overload
36%
Breast Cancer
35%
Leukemia Patients
34%
Lymphoma Patients
34%
Thalassemia
33%
COVID-19
33%
Breast Cancer Patients
31%
Plasma Fibrinogen
29%
Decompensated Cirrhosis
29%
Disease Score
29%
MELD Score
29%
Scattergram
29%
Hematology Analyzer
29%
MicroRNA-21 (miR-21)
29%
β-Thalassemia (β-thal)
29%
Rare Manifestation
29%
Cyclophosphamide
28%
Hematological Malignancies
28%
Doxorubicin
27%
Malignancy
24%
Fibrinogen
23%
Ann Arbor Staging
22%
Cell Population
20%
Early Detection
20%
Diagnostic Value
19%
Bone Marrow Aspiration
19%
COVID-19 Patients
19%
Imatinib Therapy
19%
Chronic Kidney Disease
18%
R-CHOP Chemotherapy
17%
Imatinib
17%
Transfusion-dependent Thalassemia
16%
Hematologic
16%
Diagnostic Challenge
14%
Convalescent Plasma Therapy
14%
Acute Myeloid Leukemia Cells
14%
Difference Expression
14%
Therapy Response
14%
Bacillary Dysentery
14%
Progressive multifocal Leukoencephalopathy
14%
Smoldering multiple Myeloma
14%
John Cunningham Virus
14%
Chronic Lymphocytic Leukemia
14%
Filgrastim
14%
Chemotherapy-induced Neutropenia
14%
TAC Chemotherapy
14%
Blast Cells
14%
Plasma miRNAs
14%
Screening Biomarker
14%
Financial Outcomes
14%
Out-of-pocket Payments
14%
Survival Prediction
14%
Severe COVID-19 Patients
14%
Precursor Cells
14%
Carbohydrate Antigen 15-3
14%
Cancer Stem Cells
14%
B Cells
14%
Age-matched
14%
Breast Cancer Stage
14%
Duration of Therapy
14%
Cross-cultural Analysis
14%
C-Myc
14%
Plasma microRNA
14%
Cell Line Development
14%
Breast Cancer Stem Cells
14%
MCF-7
14%
Biomarker Analysis
14%
Continuous Cell Lines
14%
Enriched Culture
14%
Dedifferentiation
14%
Priapism
14%
Reticulocyte Hemoglobin Equivalent (RET-He)
14%
Early Molecular Response
14%
Hasford Score
14%
Disseminated Histoplasmosis
14%
Waldenström Macroglobulinemia
14%
Transfusion Requirements
14%
High-sensitivity Troponin T
14%
Complementary Modalities
14%
Chelation
14%
Renal Complications
14%
WPC Channel
14%
Radiological Parameters
14%
Lymphoma Therapy
14%
Predictive Factors of Response
14%
Large Cell
14%
Response to Therapy
14%
Complementary Medicine
14%
Absolute Neutrophil Count
14%
Moderate to Severe
14%
Referral Hospital
14%
Single-center Study
14%
Adult Patients
14%
Cytarabine
14%
Medicine and Dentistry
Non-Hodgkin Lymphoma
55%
COVID-19
44%
Diffuse Large B-Cell Lymphoma
37%
Lymphocyte
37%
Cancer
31%
Diagnosis
29%
Chronic Myelogenous Leukemia
29%
Iron Overload
29%
Diseases
27%
Doxorubicin
27%
Neutrophil
25%
Treatment Response
19%
Bone Marrow Biopsy
19%
Hypochromic Anemia
19%
Health Care Cost
18%
Biological Marker
17%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
17%
Malignant Neoplasm
16%
Case Presentation
14%
JC Virus
14%
Hematology
14%
B-Cell Chronic Lymphocytic Leukemia
14%
Progressive Multifocal Leukoencephalopathy
14%
Smouldering Myeloma
14%
Lymphoma Cell
14%
Complementary Medicine
14%
Cell Line
14%
Acute Myeloid Leukemia
14%
Pericardial Fluid
14%
Cancer Stem Cell
14%
MCF-7
14%
Breast Cancer
14%
Leukemia Cell
14%
Blast Cell
14%
Cell Dedifferentiation
14%
Lung Cancer
14%
Cytarabine
14%
Cell Culture
14%
Priapism
14%
Reticulocyte
14%
Precursor
14%
Histoplasmosis
14%
Imatinib
14%
First Trimester Pregnancy
14%
Waldenström's Macroglobulinemia
14%
Beta Thalassemia
14%
Troponin T
14%
Predictive Factor
14%
Liposomal Daunorubicin
14%
Cell Population
14%
Thalassemia Major
14%
C Reactive Protein
14%
Chronic Kidney Disease
14%
Pancytopenia
14%
Cardiotoxicity
14%
Large Cell
14%
Systematic Review
14%
B Cell
14%
Splenomegaly
14%
Cerebral Hemorrhage
14%
Dysentery
14%
Prospective Cohort Study
14%
Evans Syndrome
14%
Tamponade
14%
Placebo
14%
Hydroxychloroquine
14%
Chloroquine
14%
Side Effect
14%
Iron Chelating Agent
14%
C-Terminal Telopeptide
14%
Capecitabine
14%
Medical Oncology
14%
Chemotherapy
13%
Vincristine
13%
Prednisone
13%
Cyclophosphamide
13%
Heart Left Ventricle Ejection Fraction
13%
Anemia
12%
Household
12%
Ferritin
12%
Rituximab
12%
Iron
12%
Chelation Therapy
11%
Oncology
11%
FOLFIRI
11%
Neck
9%
Lactate Dehydrogenase
9%
Cytotechnology
9%
Multiple Myeloma
9%
Outpatient
9%
CHOP
9%
Prevalence
8%
Infection
8%
Medical Record
8%
Dyspnea
7%
Artificial Respiration
7%
Chronic Myelogenous Leukemia
7%
Peripheral Blood Mononuclear Cell
7%
Computer Assisted Tomography
7%
Patient with Non-Hodgkins Lymphoma
7%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
100%
Nonhodgkin Lymphoma
56%
Imatinib
44%
Chronic Myeloid Leukemia
44%
Diffuse Large B Cell Lymphoma
39%
Diseases
36%
Iron Poisoning
33%
End Stage Liver Disease
29%
Decompensated Liver Cirrhosis
29%
Fibrinogen
29%
Breast Cancer
29%
Ferritin
27%
Cyclophosphamide
24%
Doxorubicin
23%
Iron Deficiency Anemia
19%
Chronic Kidney Failure
19%
Blood Clotting Disorder
19%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
17%
Biological Marker
17%
Hematologic Malignancy
17%
Malignant Neoplasm
15%
Chronic Lymphatic Leukemia
14%
JC Virus
14%
Progressive Multifocal Leukoencephalopathy
14%
Docetaxel
14%
Neutropenia
14%
Filgrastim
14%
Acute Myeloid Leukemia
14%
microRNA 21
14%
Survival Prediction
14%
Cytarabine
14%
C Reactive Protein
14%
Troponin T
14%
Daunorubicin
14%
Cell Culture
14%
Thalassemia Major
14%
Chelating Agent
14%
Thalassemia
14%
Cardiotoxicity
14%
Beta Thalassemia
14%
Ischemic Heart Disease
14%
Colorectal Carcinoma
14%
Placebo
14%
Coronavirinae
14%
Chloroquine
14%
Hydroxychloroquine
14%
Collagen Type 1
14%
Telopeptide
14%
Osteocalcin
14%
Gemcitabine
14%
Adenocarcinoma
14%
Thrombosis
14%
Deep Vein Thrombosis
14%
Capecitabine
14%
Iron
12%
Inflammation
11%
Chelation Therapy
11%
Lactate Dehydrogenase
11%
Neoplasm
11%
Cross-Sectional Study
10%
Vincristine
10%
Prednisone
10%
Side Effect
7%
Infection
7%
Rituximab
6%
Anemia
6%
Febrile Neutropenia
6%
SARS Coronavirus
5%